Evenals in het geval van endocriene therapie bij kanker (zie deel I), kunnen ook andere doelgerichte behandelingen interfereren met fysiologische processen waardoor schade of bijwerkingen aan hart of bloedvaten kunnen optreden. Dit zal dan doorgaans te maken hebben met onbedoelde blokkade van groeifactoren die van belang zijn voor de regeneratie en functie van deze organen.
Bronnen:
- Maurea N, Coppola C, Piscopo G et al. Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors. Cardiovasc Med. 2016;17 (suppl 1):e19-e26,Rupert CE, and Coulombe KLK. The Roles of Neuregulin-1 in Cardiac Development, Homeostasis, and Disease. Biomarker Insights. 2015:10(S1) 1-9. ,Sandoo A, Kitas GD, Carmichael AR. Breast cancer therapy and cardiovascular risk: focus on trastuzumab Vascular Health and Risk Management. 2015;11:223-8.,Herrmann J, Eric H. Yang EH Iliescu C, et al. Vascular Toxicities of Cancer Therapies: The Old and The New – An Evolving Avenue. Circulation. 2016;133: 1272-89.,LI W, Croce K, Steensma DP, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. J Am Coll Cardiol 2015;66:1160-78.,Lankhorst S, Saleh L, Danser AJ, et al. Ethiology of angiogenesis inhibition-related hypertension. Curr Opin Pharmacol. 2015;21:7-13.,Grandin EW, Ky B, Cornell RF, et al. Patterns of Cardiac Toxicity Associated With Irreversible Proteasome Inhibition in the Treatment of Multiple Myeloma. J Cardiac Fail. 2015;21:138-44.,McMullen JR, Boey EJH, Ooy JYY, et al. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014;124: 3829-30.,Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. N Engl J Med. 2016;375:1457-67.,Escalante CP, Chang YC, Liao K, et al. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-74.,Aghel N, Delgado DH, Lipton JH. Cardiovascular toxicities of BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: preventive strategies and cardiovascular surveillance. Vasc Health Risk Manag. 2017;13:293-303.,Murakami N, Riella LV, Funakoshi T. Risk of Metabolic Complications in Kidney Transplantation After Conversion to mTOR Inhibitor: A Systematic Review and Meta‐Analysis. Am J Transplantation. 2014;14:2317-27. ,Glass CK, Mitchell RN. Winning the battle, but losing the war: mechanisms and morphology of cancer-therapy-associated cardiovascular toxicity. Cardiovasc Pathol. 2017;30:55-63.,Krönke J, Udeshi N, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014:343:301-5.,Giuliani M, Janji B, Berchem G. Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression. Oncotarget. 2017;8:24031-44.,Holstein SA, McCarthy PL. Immunomodulatory Drugs in Multiple Myeloma: mechanisms of Action and Clinical Experience. Drugs. 2017;77:505-20.,Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158-68.,Maurea N, Spallarossa P, Cadeddu C, et al. A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. J Cardiovasc Med. 2016;17 (suppl 1):e93-e104.,Maas AHEM, Ottevanger N, Atsma F, et al. Cardiovascular surveillance in breast cancer treatment: A more individualized approach is needed. Maturitas. 2016; 89:58-62.